Seriously speaking, has there ever been a cancer targeted drug which does not in almost 100% of the cases need expected reformulation? I think it is a wink wink oxymoron to assume otherwise, yet the vocabulary of caution demands each trial has a goal of perfection, as it should be of course.
Market Data 
Markets 
AI
